9 天前 - … 28.8% of patients who received ICI rechallenge experienced the same immune-related
adverse events (irAEs) observed with the initial ICI treatment for various malignancies [8]…

9 天前 - … Immune checkpoint inhibitors rarely cause immune… a patient who developed
immune-related adverse events (… was successfully treated with high-dose steroids and …

9 天前 - … is limited regarding PG treatment with IL-23 inhibitors. This … inhibitors was beneficial
in treatment of refractory PG. IL-23 inhibitors may be a relatively safe and effective treatment …

10 天前 - … Immune checkpoint inhibitors (ICI) cause immune-related adverse effects (irAEs)
in over a third of patients. … and mortality in ICI-treated cancer patients of different ethnic/racial …

11 天前 - … Immune checkpoint inhibitors (ICIs) like pembrolizumab are increasingly used for
treating … of immune-related adverse events (irAEs), which, although infrequent, can be severe. …

11 天前 - … This study provides a comprehensive analysis of immune-related adverse events
(irAEs… , within a large cohort of patients receiving immune checkpoint inhibitors (ICIs). Our …

12 天前 - … Immune checkpoint inhibitors (ICI) represent a major advance in the treatment of
cancer… However, they can also induce a wide variety of immune-related adverse events (irAE) […

12 天前 - … All adult patients (aged ≥ 20 yr) with solid cancer and endocrine immune-related
adverse events (irAEs) who started immunotherapy were screened for inclusion in the …

12 天前 - … Surprisingly, the patient experienced no immune-related adverse event and remained
in … choice after managing immune-related cholecystitis induced by other PD-1 antibodies. …

12 天前 - … Myocarditis is the most common and potentially fatal cardiovascular immune-related
adverse event associated with ICIs. At the same time, other cardiotoxicities include …